Category Archives: Inside BIO Industry Analysis

BIO releases largest study ever on clinical development success rates

On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success. “This study provides a wealth of information about drug development success rates Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

The Guardian: Global defence system to fight virus threats urgently needed

ebola

Fresh on the heels of the recent Ebola epidemic, the current Zika virus threat has many asking what to better prepare for such infectious disease outbreaks. Writing in The Guardian, Trevor Mundel of the Gates Foundation and Jeremy Farrar of the Wellcome Trust have some suggestions: A healthy body has three essential systems for staying that way. There is physical fitness, building resilience against threats. There is the brain, to spot danger and take action. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Improving Oncology Clinical Trials

Trial Design

The 18th Annual BIO CEO & Investor Conference kicked off with a panel focused on oncology therapeutics. A group of clinical trial experts gathered Monday morning in New York to discuss how to improve success in drug development. In particular, they explored alternative models for clinical trial design to reach higher success rates. As a lead-in to the challenge faced, preliminary data from BIO and BioMedTracker was presented on clinical development success rates [here, and upcoming data here]. The key takeaway: the most recent decade of data shows oncology Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

2015 FDA Approvals: Highest Levels in Over a Decade

btn-dave-thomas

2015 was a blockbuster year for FDA approvals of novel new medicines, many of them for serious and life-threatening conditions. As Dr. John Jenkins of the FDA’s Center for Drug Evaluation and Research (CDER) notes in a recent blog post, “During this past year, we approved many new drugs to treat various forms of cancer, including four to treat multiple myeloma, and others to treat lung, skin, breast, brain, colorectal, and other cancers. We also Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Interstitial Cystitis: Understanding What It Is, and the Interstitial Cystitis Association’s Role in an IC Patient’s Life

scientist, lab

If you mention Interstitial Cystitis (IC) to most people, including physicians, the majority of people have no idea what you are talking about. This is alarming because IC affects between 4-12 million people, just in the U.S. alone.  The majority of IC patients are women, but both men and children can receive the diagnosis as well.  So what is IC and how do you know if you have it? Interstitial cystitis (in-ter-stish-uhl sĭ-stī’tĭs), or as Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post